Every 8-K that Co-Diagnostics, Inc. (CODX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CODX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CODX filings page.
Co-Diagnostics, Inc. adjourned its annual meeting after it failed to achieve a quorum on September 3 and again on September 24, 2026. The reconvened meeting is scheduled for September 30, 2026, at 9:00 a.m. Mountain Time at the company’s offices in Salt Lake City. Stockholders will vote as described in the definitive proxy statement, and valid proxies submitted before the reconvened meeting remain effective unless properly changed or revoked before votes are taken.
Co-Diagnostics, Inc. (CODX) reports that on September 16, 2026 it will host an investor and analyst presentation. The presentation will cover the company’s collaboration with ReadyGo Diagnostics Ltd., its Co-Dx PCR platform and related development activities, manufacturing initiatives, and operations in India.
The slide deck for this event is provided as an Investor and Analyst Presentation dated September 16, 2026 and furnished as Exhibit 99.1 under a Regulation FD disclosure, meaning it is supplied for informational purposes and is not treated as filed under the Exchange Act.
Co-Diagnostics, Inc. (CODX) reported a new collaboration with ReadyGo Diagnostics Ltd. to evaluate using ReadyGo’s GoCollect® blood sample-preparation technology with the Co-Dx® PCR platform for blood-based molecular testing at the point of need, initially focused on decentralized Ebola virus detection and outbreak response.
The companies have begun feasibility work to assess workflow compatibility, building on Co-Diagnostics’ earlier Ebola plasma proof-of-concept. Success could extend the Co-Dx PCR platform beyond swab-based testing into bloodborne pathogens such as HIV and hepatitis B and C, though each application would require separate development, validation, and regulatory authorization and there is no assurance of a commercial product.
Co-Diagnostics, Inc. (CODX) reported that in August 2026 it entered into a material transfer agreement with ReadyGo Diagnostics Ltd to evaluate the compatibility of ReadyGo’s sample collection and preparation technologies with the Co-Dx PCR platform. ReadyGo will supply sampling materials for feasibility, evaluation and compatibility testing.
The company believes ReadyGo’s technologies may complement the Co-Dx PCR platform’s goal of enabling real-time PCR testing in decentralized and point-of-care settings by simplifying sample collection, stabilization and preparation. The evaluation is preliminary, does not obligate either party to any development, supply or commercialization agreement, and may not result in any further relationship. The Co-Dx PCR platform and associated tests remain subject to regulatory review and are not currently available for sale.
Co-Diagnostics, Inc. (CODX) reported that Chief Financial Officer Brian Brown’s employment ended on September 2, 2026, which was his last day serving as the company’s principal financial officer and principal accounting officer. On the same date, Daniel Bohrer, Executive Vice President of Finance and Accounting, was designated as the new principal financial officer and principal accounting officer.
In connection with this appointment, Mr. Bohrer’s annual salary increased from $225,000 to $255,000. The company notes that Mr. Bohrer, age 49, has extensive prior experience in finance, accounting, and audit roles at Co-Diagnostics, Workfront, Inc., and EY, and that he has no family relationships, related person transactions, or selection arrangements with other company insiders.
Co-Diagnostics, Inc. (CODX) reported that its September 3, 2026 Annual Meeting of Stockholders did not achieve a quorum, so no business could be conducted. Under the company’s bylaws, the chairperson adjourned the meeting.
The Annual Meeting is adjourned to September 24, 2026 at 9:00 a.m. Mountain Time, to be held at the company’s offices at 2401 S. Foothill Dr, Ste. D, Salt Lake City, Utah 84109. Stockholders may participate and vote as described in the definitive proxy statement filed on July 21, 2026, and all valid proxies already submitted will remain effective for the reconvened meeting unless changed or revoked before votes are taken.
Co-Diagnostics, Inc. reported second quarter 2026 results that reflect early commercialization efforts and substantial investment in its Co-Dx PCR platform. Revenue was $0.17 million, roughly flat with the prior-year quarter, and gross profit was modest at $0.12 million on low sales volumes.
The company continued to prioritize R&D and platform build-out, with operating expenses of $6.3 million, down from $8.2 million a year earlier, leading to a reduced operating loss of $6.2 million. Net loss improved to $6.3 million, or $1.46 per share, and adjusted EBITDA loss narrowed to $5.8 million. Cash and cash equivalents declined to $3.6 million as of June 30, 2026, partially offset by a $3.0 million private placement that strengthened near-term liquidity.
Operationally, Co-Diagnostics completed clinical and analytical studies for its Co-Dx PCR Flu A/B & RSV test and submitted an FDA 510(k) and concurrent CLIA Waiver by Application, a key step toward U.S. commercialization of its point-of-care platform, which is not yet cleared or available for sale. The company advanced international manufacturing through CoMira in Saudi Arabia, expanded TB and Ebola-related programs via CoSara in India, and grew its Vector Smart vector-surveillance footprint to 21 U.S. states, while adding a new Chief Scientific Officer to lead scientific and regulatory strategy.
Co-Diagnostics, Inc. entered into an inducement agreement on July 30, 2026 under which holders of existing warrants agreed to exercise warrants for 1,702,362 shares of common stock at $1.571 per share. In return, the company will issue new five-year warrants to purchase up to 3,404,724 shares at an exercise price of $1.56 per share, exercisable only after required stockholder approval under Nasdaq rules. The company expects gross cash proceeds of about $2.67 million from the warrant exercises, before a 7.0% placement fee to Maxim Group LLC and $50,000 of expense reimbursement.
Common shares outstanding will increase from 5,277,846 to 6,980,208 upon closing, expected on or about August 3, 2026. Co-Diagnostics agreed not to issue additional common stock or equivalents or file other registration statements (with limited exceptions) until August 31, 2026, and to seek prompt stockholder approval of the new warrant exercises. The company will file a resale registration statement for the new warrant shares and the warrants include cashless exercise features, anti-dilution adjustments, a beneficial ownership cap of 4.99% (or 9.99% by election), and Fundamental Transaction protections based on Black Scholes Value.
Co-Diagnostics, Inc. entered into an amendment to its Equity Distribution Agreement with Maxim Group LLC on July 27, 2026. The amendment removes the fixed aggregate dollar cap on sales, so future offers and sales of common stock under this arrangement are limited only by the amount of stock currently registered and available under the effective Shelf Registration Statement No. 333-295803 and the related prospectus supplement dated July 27, 2026.
In connection with this amendment, the company agreed with investors under a Securities Purchase Agreement dated May 19, 2026 to extend the period during which it will not issue or agree to issue common stock or equity-linked securities, or file related registration statements, until 5:00 pm Eastern Time on August 14, 2026. The company also clarified that this report does not itself constitute an offer to sell or solicitation to buy any shares.
Co-Diagnostics, Inc. entered into a private placement to raise approximately $3.0 million in gross proceeds from institutional and accredited investors. The company is selling 54,915 common shares, pre-funded warrants for 1,592,532 shares, and common warrants for 3,294,894 shares, primarily for general corporate purposes and working capital.
The securities are priced at a combined $1.821 per share (or pre-funded warrant) and accompanying warrants, with common warrants exercisable at $1.571 per share for five years. Company insiders agreed to 60-day lock-ups, and Co-Diagnostics committed to file a resale registration statement and observe temporary restrictions on additional and variable-rate financings.
Co-Diagnostics, Inc. reported first-quarter 2026 revenue of $0.15 million, up from $0.05 million a year earlier, but remained deeply loss-making. Operating expenses were $9.2 million, leading to an operating loss of $9.2 million and a net loss of $9.1 million, or $4.06 per share, compared with a $7.5 million loss, or $7.05 per share, in 2025.
Cash and cash equivalents were $8.2 million as of March 31, 2026, down from $11.9 million at year-end, while adjusted EBITDA loss widened to $8.7 million from $7.4 million. Management highlighted regulatory and commercial progress, including an Indian CDSCO license and ISO 13485 certification for the CoSara PCR Pro instrument, expansion of South Asian distribution to a roughly $13 billion market, and preparation for a 510(k) submission for an upper respiratory multiplex test and TB clinical studies in India.
Co-Diagnostics reported sharply weaker 2025 results. Revenue fell to $0.6 million from $3.9 million in 2024, mainly from lower grant revenue, while an $18.9 million intangible impairment helped drive an operating loss of $50.2 million and a net loss of $46.9 million, or $35.25 per share.
Adjusted EBITDA loss improved to $28.0 million from $33.5 million, but cash, cash equivalents and marketable securities dropped to $11.9 million from $29.7 million, reducing financial flexibility. Management highlighted progress on its PCR platform, AI-enabled Primer Ai platform, and joint ventures CoSara in India and CoMira in Saudi Arabia, including new patents and regional expansion agreements.
Co-Diagnostics, Inc. reports that Nasdaq has confirmed the company is back in compliance with the $1.00 minimum bid price and other requirements for continued listing on The Nasdaq Capital Market. Trading in its securities is scheduled to resume on Nasdaq with the market open on March 11, 2026.
Nasdaq’s Hearing Panel will monitor the company for one year, through March 9, 2027; if the closing bid price stays below $1.00 for 30 consecutive business days, a delisting determination would be issued, subject to appeal. The company also preliminarily estimates cash and cash equivalents of about $11.9 million as of December 31, 2025, an unaudited figure that may change after year-end closing procedures.
Co-Diagnostics, Inc. reports that Nasdaq has determined to delist its common stock from The Nasdaq Capital Market because the company has not met the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). Trading in its shares is scheduled to be suspended on January 14, 2026, and the stock is expected to trade on the Pink Limited Information tier of the OTC Market under the symbol CODX.
The company plans to request a hearing before a Nasdaq Hearings Panel and notes that, after a 1-for-30 reverse stock split effective January 2, 2026, its closing bid price has been at or above $1.00 per share. If it maintains at least a $1.00 closing bid for 10 consecutive business days ending January 15, 2026, it will seek a compliance determination and cancellation of the hearing, though there is no assurance it will regain compliance or avoid the trading suspension.
Co-Diagnostics (CODX) furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The company issued a press release attached as Exhibit 99.1, which includes a non-GAAP financial measure. The disclosures under Items 2.02 and 7.01 are furnished, not filed, and are not subject to Section 18 of the Exchange Act, nor incorporated by reference except as expressly stated.
Co-Diagnostics, Inc. entered a securities purchase agreement for a registered direct offering, selling 12,002,272 shares at $0.55 per share and 725,000 pre-funded warrants at $0.5499 each. The pre-funded warrants carry a $0.0001 exercise price, are exercisable immediately, and expire upon full exercise.
Gross proceeds are expected to be approximately $7 million, before fees and expenses. The company engaged Maxim Group LLC as placement agent for a cash fee equal to 7.0% of gross proceeds, plus up to $50,000 in reimbursable expenses. Closing is expected on October 29, 2025. Proceeds are earmarked for working capital and general corporate purposes. A beneficial ownership cap limits warrant exercises to 4.99% or 9.99% of outstanding shares, as applicable.
Co-Diagnostics, Inc. entered into a securities purchase agreement for a registered direct offering of 9,619,000 shares of common stock at $0.40 per share to two institutional investors, for expected gross proceeds of about $3.8 million before fees and expenses. The deal is being conducted under an effective Form S-3 shelf registration and is expected to close on September 18, 2025, with Maxim Group LLC acting as exclusive placement agent.
The company will pay the placement agent a cash fee of 7.0% of gross proceeds and reimburse up to $50,000 of expenses, and plans to use the net proceeds for working capital and general corporate purposes. Each investor received rights to participate in up to 30% of any subsequent financing for 12 months, subject to a 4.99% or 9.99% beneficial ownership cap and certain issuance restrictions on new common stock or equivalents for 30 days after closing.